REGN20423 for Atopic Dermatitis

(AURA-AD Trial)

This trial explores a new medicine called REGN20423 to evaluate its effectiveness for people with eczema, also known as atopic dermatitis. Researchers aim to identify any side effects, determine the medicine's concentration in the blood, and assess if the body produces antibodies in response. They also seek to understand why it might work better for some individuals and to determine the optimal dose. Part A of the trial welcomes healthy individuals, while Part B seeks participants who have had eczema for at least six months and experience noticeable symptoms. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Yes, participants in Part B of the trial must stop taking certain medications and treatments before starting and during the study, as specified in the Excluded Medications and Treatments list.

In a groundbreaking study, researchers are testing a new treatment called REGN20423 in both healthy individuals and those with eczema. Since this marks the first human trial of REGN20423, no previous safety information exists. Scientists are still learning how people might respond to it. In early trials like this one, researchers closely monitor any side effects and how well participants tolerate the treatment.

Unlike the standard treatments for atopic dermatitis, which typically include topical corticosteroids and calcineurin inhibitors, REGN20423 offers a potentially groundbreaking approach. This investigational treatment targets specific immune pathways involved in the inflammatory process, which could lead to more precise control of symptoms. Researchers are excited about REGN20423 because it could provide relief with fewer side effects and potentially offer a faster onset of action compared to current options. This novel mechanism of action could make a significant difference for patients who have not found success with existing therapies.

Research has shown that many people have atopic dermatitis, also known as eczema, with about 40-50% experiencing moderate-to-severe symptoms. Recent treatments aim to reduce symptoms like itching and skin inflammation by targeting specific parts of the immune system. REGN20423, a new treatment under study in this trial, is designed to interact with certain immune system pathways to reduce inflammation. Although REGN20423 has not yet been tested in humans, similar treatments have shown promise. Participants in this trial will be assigned to either Part A or Part B to evaluate the effects of REGN20423.⁴⁶⁷⁸⁹